Eligible patients:Â
Men and women age ≥ 18 years with confirmed invasive lobular breast cancer and suspected or known metastatic disease. Additional eligibility criteria can be found here.
Description of Trial/Summary:
This pilot study evaluates a novel PET imaging agent (PYLARIFY, piflufolastat F18) in patients with suspected or confirmed metastatic cancer, including invasive lobular breast cancer. Participants will undergo PET/CT imaging to assess how accurately this approach detects metastatic lesions compared to standard imaging and biopsy results. The study aims to determine whether this imaging method can better identify the extent of disease.
Why is this study beneficial?/Important?
Accurate detection of metastatic disease remains a challenge in invasive lobular breast cancer, where standard imaging can underestimate disease burden. This study explores a new imaging tracer that may improve visualization of metastases and provide additional clinical information. Although not specific to ILC, it includes patients with lobular breast cancer and may help expand imaging options for this population.
Principal Investigator:
Yang Lu, MD, PhD
More information/Trial Contact:
Yang Lu, MD, PhD
Phone: (713) 792-5768
Email: ylu10@mdanderson.org
Trial Location:
M.D. Anderson Cancer Center, Houston, Texas, USA
For more information:
https://clinicaltrials.gov/study/NCT05394259#study-overview